Alterations to fibroblast growth factor receptor (FGFR) genes are a prevalent potential driver of disease in oncology, with continuous activation of the FGFR pathway driving multiple tumourigenic processes across tumour types. As altered FGFR signalling is common in a wide variety of cancers, FGFR alterations represent an important potential target. The most commonly affected are urothelial carcinomas (UCs) with FGFR alterations identified across all grades and stages of bladder cancer.
The improved understanding of the role FGFR alterations have in oncology could mean you will be able to see your patients’ potential tumour drivers more clearly.